文献速递头颈与中枢神经肿瘤支持与姑息治疗

预防性抗生素减少局部晚期头颈癌放化疗患者的住院率和费用:一项随机2期研究

Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study.
PubMed 文献 · Eur J Cancer · 2019-04-06

这项多中心随机2期研究纳入95例局部晚期头颈癌放化疗患者,比较预防性阿莫西林/克拉维酸与标准护理。预防性抗生素未减少肺炎发生率(标准组45.8% vs 预防组46.8%,p=0.54),但显著降低住院率(39.6% vs 19.1%,p=0.03)和发热发作(29.2% vs 10.2%,p=0.028),人均费用平均减少1425欧元,倾向于具有成本效益。

要点

  • 预防性阿莫西林/克拉维酸未降低放化疗期间肺炎发生率(45.8% vs 46.8%,p=0.54)。
  • 预防性抗生素显著降低住院率(39.6% vs 19.1%,p=0.03)和任何级别发热发作(29.2% vs 10.2%,p=0.028)。
  • 预防组人均费用平均减少1425欧元,倾向于具有成本效益。

核心结论

  • 预防性抗生素未减少局部晚期头颈癌放化疗患者的肺炎发生率,但显著降低住院率和发热发作,并倾向于具有成本效益。

研究设计与样本

  • 多中心随机2期试验,106例患者纳入,95例随机分组:标准组48例,预防组47例。
  • 预防组从治疗开始后第29天至放化疗完成后14天接受预防性阿莫西林/克拉维酸,标准组不接受预防。
  • 主要目标为观察肺炎减少,次要目标评估住院率、不良事件、费用和健康相关生活质量。

主要发现

  • 放化疗期间及随访至3.5个月,标准组48例中22例(45.8%)发生肺炎,预防组47例中22例(46.8%)发生肺炎(p=0.54)。
  • 标准组住院率显著高于预防组:19/48例(39.6%)vs 9/47例(19.1%)(p=0.03)。
  • 标准组任何级别发热发作显著更多:29.2% vs 10.2%(p=0.028)。
  • 费用存在显著差异,预防组人均平均减少1425欧元。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platinum-based chemoradiotherapy for locally advanced head and neck cancer (LAHNC) induces a high rate of acute toxicity, including dysphagia and aspiration pneumonia. We hypothesised that prophylactic antibiotics can prevent pneumonia and hospitalisations and can be cost-effective. PATIENT AND METHODS: In this multicentre randomised trial, patients with LAHNC treated with chemoradiotherapy received prophylactic amoxicillin/clavulanic acid from day 29 after the start of treatment until 14 days after completion of chemoradiotherapy or standard care without prophylaxis. The primary objective was to observe a reduction in pneumonias. Secondary objectives were to evaluate the hospitalisation rate, adverse events, costs and health-related quality of life. RESULTS: One hundred six patients were included; of which, 95 were randomised: 48 patients were allocated to the standard group and 47 patients to the prophylaxis group. A pneumonia during chemoradiotherapy and follow-up until 3.5 months was observed in 22 (45.8%) of 48 patients in the standard group and in 22 (46.8%) of 47 patients in the prophylaxis group (p = 0.54). Hospitalisation rate was significantly higher in the standard group versus the prophylaxis group, 19 of 48 pts (39.6%) versus 9 of 47 pts (19.1%), respectively (p = 0.03). Significantly more episodes with fever of any grade were observed in the standard group (29.2% vs 10.2%, p = 0.028). A significant difference in costs was found, with an average reduction of €1425 per patient in favour of the prophylaxis group. CONCLUSION: Although prophylactic antibiotics during chemoradiotherapy for patients with LAHNC did not reduce the incidence of pneumonias, it did reduce hospitalisation rates and episodes with fever significantly and consequently tended to be cost-effective.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ham JC, Driessen CM, Hendriks MP, et al. Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study. Eur J Cancer. 2019. PMID: 30965213. doi:10.1016/j.ejca.2019.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。